Effect of Early Administration of TXA in Adult Hip Fractures

Recruiting now · Phase 2/Phase 3

Conditions studied: Postoperative Blood Loss

In brief

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

Key facts

Study ID

NCT05047133

Run by

Ascension Health

People needed

170

Starts

2021-09-01

Expected to finish

2022-07-01

Last updated by the study team

2021-09-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 1. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation

You may not qualify if…

• Polytrauma patients
• Previous operation on the ipsilateral hip
• Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)
• Patients with < 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac Stents, or Myocardial Infarction (MI)
• History of seizure disorder
• Patients on birth control
• Pregnant Women
• Prisoners
• Active thromboembolic disease (DVT/PE, MI, Stroke)

Where it is running

• Ascension Genesys Hospital — Grand Blanc, Michigan, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.